196 related articles for article (PubMed ID: 37865511)
1. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.
Madanat YF; Zeidan AM
Clin Lab Med; 2023 Dec; 43(4):685-698. PubMed ID: 37865511
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
3. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
Xie Z; Chen EC; Stahl M; Zeidan AM
Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
[TBL] [Abstract][Full Text] [Related]
4. Current state of prognostication and risk stratification in myelodysplastic syndromes.
Zeidan AM; Gore SD; Padron E; Komrokji RS
Curr Opin Hematol; 2015 Mar; 22(2):146-54. PubMed ID: 25575032
[TBL] [Abstract][Full Text] [Related]
5. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
6. Current pathology practices in and barriers to MDS diagnosis.
Glauser TA; Sagatys EM; Williamson JC; Burton BS; Berger C; Merwin P; Sugrue M; Bennett JM
Leuk Res; 2013 Dec; 37(12):1656-61. PubMed ID: 24220584
[TBL] [Abstract][Full Text] [Related]
7. Morphologic Characteristics of Myelodysplastic Syndromes.
Yuen LD; Hasserjian RP
Clin Lab Med; 2023 Dec; 43(4):577-596. PubMed ID: 37865504
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
9. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.
Zhang X; Lancet JE; Zhang L
Leuk Lymphoma; 2015; 56(11):3022-30. PubMed ID: 25927244
[TBL] [Abstract][Full Text] [Related]
11. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron E
Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes.
Zhou J; Orazi A; Czader MB
Semin Diagn Pathol; 2011 Nov; 28(4):258-72. PubMed ID: 22195404
[TBL] [Abstract][Full Text] [Related]
13. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndromes: pathophysiology, clinical and biological features].
Becha M; Braham Jmili N
Ann Biol Clin (Paris); 2015; 73(6):643-56. PubMed ID: 26635046
[TBL] [Abstract][Full Text] [Related]
15. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of myelodysplastic syndromes in cytopenic patients.
Wang SA
Hematol Oncol Clin North Am; 2011 Oct; 25(5):1085-110, vii. PubMed ID: 22054736
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A; Nomdedeu M; Tuechler H; Garcia-Manero G; Komrokji RS; Sekeres MA; Della Porta MG; Cazzola M; DeZern AE; Roboz GJ; Steensma DP; Van de Loosdrecht AA; Schlenk RF; Grau J; Calvo X; Blum S; Pereira A; Valent P; Costa D; Giagounidis A; Xicoy B; Döhner H; Platzbecker U; Pedro C; Lübbert M; Oiartzabal I; Díez-Campelo M; Cedena MT; Machherndl-Spandl S; López-Pavía M; Baldus CD; Martinez-de-Sola M; Stauder R; Merchan B; List A; Ganster C; Schroeder T; Voso MT; Pfeilstöcker M; Sill H; Hildebrandt B; Esteve J; Nomdedeu B; Cobo F; Haas R; Sole F; Germing U; Greenberg PL; Haase D; Sanz G
Leukemia; 2021 Mar; 35(3):835-849. PubMed ID: 32595214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
